Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 45 full-time employees. The company went IPO on 2019-07-18. The firm's lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD). The company uses technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. In addition to its product candidates, the Company has developed a discovery approach that it employs to systematically identify and validate cellular drug targets that can potentially modulate gene expression to treat known root causes of genetically defined rare diseases. The firm continues to advance its program for the potential treatment of inherited aplastic anemias, such as Diamond-Blackfan anemia (DBA), Shwachman-Diamond syndrome, and Fanconi anemia.
Follow-Up Questions
Who is the CEO of Fulcrum Therapeutics Inc?
Mr. Alex Sapir is the President of Fulcrum Therapeutics Inc, joining the firm since 2023.
What is the price performance of FULC stock?
The current price of FULC is $8.99, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Fulcrum Therapeutics Inc?
Fulcrum Therapeutics Inc belongs to Pharmaceuticals industry and the sector is Health Care
What is Fulcrum Therapeutics Inc market cap?
Fulcrum Therapeutics Inc's current market cap is $486.2M
Is Fulcrum Therapeutics Inc a buy, sell, or hold?
According to wall street analysts, 9 analysts have made analyst ratings for Fulcrum Therapeutics Inc, including 4 strong buy, 6 buy, 2 hold, 1 sell, and 4 strong sell
